Delivering on the promise of mRNA therapies for rare diseases

Dr. Stephen Hoge, President, and Paolo Martini, Ph.D., CSO Rare Diseases, discuss newly published preclinical data supporting Moderna’s first rare liver disease development program, an mRNA therapeutic for methylmalonic acidemia (MMA).